Welcome to our dedicated page for Genelux news (Ticker: GNLX), a resource for investors and traders seeking the latest updates and insights on Genelux stock.
Genelux Corporation (NASDAQ: GNLX) is a late clinical-stage biopharmaceutical company in the immuno-oncology field, and this news page aggregates company announcements, clinical updates, and corporate developments related to its oncolytic immunotherapy programs. Genelux focuses on developing next-generation oncolytic vaccinia virus immunotherapeutic product candidates, led by its proprietary asset Olvi-Vec (olvimulogene nanivacirepvec).
News about Genelux frequently highlights progress in its clinical pipeline, including the Phase 3 OnPrime/GOG-3076 registrational trial in platinum-resistant/refractory ovarian cancer, the Phase 2 VIRO-25 trial in advanced or metastatic recurrent non-small cell lung cancer, and the Phase 1b/2 Olvi-Vec-SCLC-202 trial in recurrent or progressive small cell lung cancer. Company releases also describe interim data from these studies, such as observed anti-tumor activity, disease control rates, and tolerability of systemically administered Olvi-Vec in lung cancer settings.
In addition to clinical data, investors can find updates on public offerings of common stock, use of proceeds for research and development and clinical trial expenses, and governance-related items such as executive appointments and equity incentive plan changes. SEC-related disclosures, conference participation, and fireside chats with analysts are also common topics in Genelux’s news flow.
By following GNLX news, readers can track how Genelux advances its CHOICE™ platform-derived pipeline, how Olvi-Vec is being evaluated across multiple solid tumor indications, and how corporate actions support its late clinical-stage development strategy. This page provides a centralized view of the company’s press releases and public communications for those monitoring its progress in oncolytic viral immunotherapy.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Genelux Corporation (NASDAQ: GNLX), a biopharmaceutical firm specializing in oncolytic viral immunotherapies, will ring the Nasdaq opening bell on March 29, 2023, to celebrate its recent IPO in January. CEO Thomas Zindrick expressed gratitude for stakeholder support as the company seeks to establish itself in the immunotherapy sector. The event will be broadcast live from the Nasdaq MarketSite Tower in New York City. Genelux's core product, Olvi-Vec, is a modified vaccinia virus designed to treat aggressive solid tumors, developed from the proprietary CHOICE™ platform. More details can be found at www.genelux.com.
Genelux Corporation has announced the pricing of its initial public offering (IPO) of 2,500,000 shares at $6.00 per share, totaling approximately $15.0 million in gross proceeds. The shares are set to trade on the Nasdaq under the ticker symbol GNLX, starting January 26, 2023, with the offering closing on January 30, 2023, pending customary conditions. The underwriters have a 30-day option to purchase an additional 375,000 shares. This capital will support Genelux's pipeline of oncolytic viral immunotherapies targeted at aggressive solid tumors, leveraging its proprietary CHOICE™ platform.